STAR LAKE BIOSCIENCE CO., INC.ZHAOQING GUANGDONG Financials Star Lake Bioscience Co., Inc.Zhaoqing Guangdong
Equities
600866
CNE000000H46
Food Processing
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.4 CNY | -1.39% |
|
-7.11% | +37.34% |
| Apr. 23 | China stocks down, dragged by cyclical shares; HK shares up | RE |
| Apr. 22 | Star Lake Bioscience Co., Inc.Zhaoqing Guangdong Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,281 | 9,853 | 7,742 | 10,633 | - | - |
| Enterprise Value (EV) 1 | 3,281 | 9,853 | 7,742 | 10,633 | 10,633 | 10,633 |
| P/E ratio | 21.9 x | 11.6 x | 11.4 x | 9.7 x | 8.77 x | - |
| Yield | - | - | - | 4.38% | 4.69% | 4.69% |
| Capitalization / Revenue | 3.13 x | - | - | 0.6 x | 0.57 x | 0.54 x |
| EV / Revenue | 3.13 x | - | - | 0.6 x | 0.57 x | 0.54 x |
| EV / EBITDA | 13 x | - | - | 4.45 x | 4.08 x | 3.76 x |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 2.16 x | - | - | 1.29 x | 1.19 x | 1.08 x |
| Nbr of stocks (in thousands) | 739,019 | 1,661,473 | 1,661,473 | 1,661,473 | - | - |
| Reference price 2 | 4.440 | 5.930 | 4.660 | 6.400 | 6.400 | 6.400 |
| Announcement Date | 3/16/20 | 3/27/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,050 | - | - | 17,753 | 18,765 | 19,703 |
| EBITDA 1 | 251.5 | - | - | 2,392 | 2,608 | 2,829 |
| EBIT 1 | 163.1 | - | - | 1,406 | 1,559 | 1,728 |
| Operating Margin | 15.54% | - | - | 7.92% | 8.31% | 8.77% |
| Earnings before Tax (EBT) 1 | 157.4 | - | - | 1,403 | 1,555 | 1,725 |
| Net income 1 | 149.6 | 608.3 | 678 | 1,101 | 1,221 | 1,354 |
| Net margin | 14.25% | - | - | 6.2% | 6.51% | 6.87% |
| EPS 2 | 0.2024 | 0.5122 | 0.4080 | 0.6600 | 0.7300 | - |
| Free Cash Flow | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | 0.2800 | 0.3000 | 0.3000 |
| Announcement Date | 3/16/20 | 3/27/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | 11.1% | - | - | 13.4% | 13.6% | 13.8% |
| ROA (Net income/ Total Assets) | 8.4% | - | - | 6.5% | 6.7% | 6.9% |
| Assets 1 | 1,781 | - | - | 16,938 | 18,224 | 19,623 |
| Book Value Per Share 2 | 2.060 | - | - | 4.950 | 5.390 | 5.900 |
| Cash Flow per Share 2 | 0.2900 | - | - | 1.240 | 1.370 | 1.620 |
| Capex 1 | 157 | - | - | 1,116 | 1,116 | 916 |
| Capex / Sales | 15% | - | - | 6.29% | 5.95% | 4.65% |
| Announcement Date | 3/16/20 | 3/27/23 | 4/22/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
6.4
CNY
Average target price
7.92
CNY
Spread / Average Target
+23.75%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +37.34% | 1.47B | |
| -5.67% | 27.45B | |
| +18.78% | 24.56B | |
| +5.34% | 11.01B | |
| +11.49% | 5.11B | |
| +14.97% | 4.33B | |
| -13.08% | 3.62B | |
| -5.98% | 2.8B | |
| +25.30% | 2.75B | |
| -5.32% | 2.17B |
- Stock Market
- Equities
- 600866 Stock
- Financials Star Lake Bioscience Co., Inc.Zhaoqing Guangdong
